ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 3125 • 2015 ACR/ARHP Annual Meeting

    White Matter Magnetization Transfer Ratio Histogram Peak Height Helps Identifying Inflammatory Neuropsychiatric Systemic Lupus Erythematosus

    César Magro Checa1, Ece Ercan2, Bart J Emmer3, Ron Wolterbeek4, Itamar Ronen2, Mark A. Van Buchem2, T. W. J. Huizinga5 and Gerda M. Steup-Beekman5, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Radiology, C.J. Gorter Center for High Field MRI, Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Radiology, Erasmus Medical Center, Rotterdam, Netherlands, 4Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, Netherlands, 5Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Magnetization transfer ratio (MTR) can be used to detect microstructural cerebral changes in normal-appearing brain tissue of neuropsychiatric systemic lupus erythematosus (NPSLE) patients. Our…
  • Abstract Number: 3126 • 2015 ACR/ARHP Annual Meeting

    Biomarkers Associated with Hyperintense White Matter Lesions in Systemic Lupus Erythematosus

    Mariana Postal, Aline Tamires Lapa, Karina O. Peliçari, Nailu A. Sinicato, Fernando A. Peres, Angela C. Gomes, Lilian TL Costallat, Fernando Cendes and Simone Appenzeller, Medicine, State University of Campinas, Campinas, Brazil

    Background/Purpose: Cytokines and neuronal injury markers act as crucial mediators in the bidirectional signaling between the immune system and the brain and may be biomarkers…
  • Abstract Number: 3127 • 2015 ACR/ARHP Annual Meeting

    Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®

    Chaim Putterman1, D. Scott Batty2, I.R. Cohen3, Nicole Jordan4, Debbie Rybak1, Tamar Rubinstein1, Keren Jakobi5, Rachel Sorek5, Anat Reiner-Benaim5, Yakov Blumenstein5 and Pennina Safer5, 1Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 2ImmunArray Inc., Richmond, VA, 3Weizmann Institute of Science, Rehovot, Israel, 4Montefiore Medical Center, New York, NY, 5ImmunArray LTD, Rehovot, Israel

    Background/Purpose: Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in systemic lupus erythematosus (SLE). Neuropsychiatric SLE (NPSLE) involves…
  • Abstract Number: 3128 • 2015 ACR/ARHP Annual Meeting

    Genome-Wide DNA Methylation Analysis in Blood and Dermal Fibroblasts from Twin Pairs Discordant for Systemic Sclerosis

    Paula S. Ramos1, Thomas A. Medsger Jr.2 and Carol A. Feghali-Bostwick1, 1Medicine, Medical University of South Carolina, Charleston, SC, 2Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The etiology and mechanisms underlying the wide variation in disease heterogeneity and severity in systemic sclerosis (SSc) remain unknown. To assess the role of…
  • Abstract Number: 3129 • 2015 ACR/ARHP Annual Meeting

    Integrative Analysis of the Colonic Microbiota in Systemic Sclerosis

    Elizabeth R. Volkmann1, Yu-Ling Chang2, Nashla Barroso3, Daniel E. Furst3, Philip J. Clements1, Alan Gorn4, Bennett Roth3, Jeffrey Conklin3, Terri Getzug3, Maomeng Tong2, Jonathan Jacobs3 and Jonathan Braun2, 1Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Pathology and Laboratory Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA

    Background/Purpose: Gastrointestinal tract (GIT) dysfunction is a leading cause of morbidity in patients with systemic sclerosis (SSc). However, the etiology of SSc-related lower GIT dysfunction…
  • Abstract Number: 3130 • 2015 ACR/ARHP Annual Meeting

    Epstein-Barr Virus Induces Activation of Infammatory Markers Via the TLR8 Transduction Pathway in Infected Scleroderma Monocytes

    Antonella Farina1, Giovanna Peruzzi2,3, Valentina Lacconi4, Edoardo Rosato5, Silvia Quarta6, Stefania Morrone1, Alberto Faggioni1, Maria Trojanowska4 and Giuseppina Alessandra Farina4, 1Department of Experimental Medicine, Sapienza University, Department of Experimental Medicine, Rome, Italy, 2Istituto Italiano di Tecnologia (IIT), CLNS@Sapienza, Rome, Italy, 3Istituto Italiano di Tecnologia (IIT), CLNS@Sapienza, Viale Regina Elena 291, 00161, Rome, Italy, Rome, Italy, 4Arthritis Center, Boston University, Arthritis Center, Boston, MA, 5Department of Clinical Medicine, Clinical Immunology Unit,, Sapienza University,Department of Clinical Medicine, Rome, Italy, 6Department of Clinical Medicine, Clinical Immunology Unit., Sapienza University,Department of Clinical Medicine, Rome, Italy

    Background/Purpose: Monocytes from patients with systemic sclerosis (Scleroderma, SSc), are characterized by the increased expression of IFN-regulatory genes, implicating dysregulation of the innate immune response…
  • Abstract Number: 3131 • 2015 ACR/ARHP Annual Meeting

    Interferon Regulatory Factor 7 (IRF7): The Possible Link Between Inflammation and Fibrosis in SSc Pathogenesis

    Minghua Wu1, Gloria Salazar1, Xiaodong Zhou2, Xinjian Guo2, John D. Reveille3, Sandeep K. Agarwal4, Michael R. Blackburn5, Maureen D Mayes1 and Shervin Assassi1, 1Rheumatology, University of Texas Medical School at Houston, Houston, TX, 2Internal Medicine, University of Texas Medical School at Houston, Houston, TX, 3Internal Medicine/Rheumatology, University of Texas Medical School at Houston, Houston, TX, 4Internal Med, Rheumatology, Baylor College of Medicine, Houston, TX, 5Biochemistry and Molecular Biology, The University of Texas Medical School at Houston, Houston, TX

    Background/Purpose: A recent global gene expression profile study in a large early SSc patient samples revealed a type I interferon (IFN) signature. Type I IFN…
  • Abstract Number: 3132 • 2015 ACR/ARHP Annual Meeting

    Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis Via Repressing Pro-Angiogenic Factors

    Pei-Suen Tsou1,2, M. Asif Amin3, Elena Schiopu2,4, David A. Fox3, Dinesh Khanna1,2 and Amr H. Sawalha1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2University of Michigan Scleroderma Program, Ann Arbor, MI, 3Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 4Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Scleroderma (SSc) is a complex disease characterized by inflammation, vascular complications, and excessive deposition of extracellular matrix. Vascular dysfunction represents a disease initiating event…
  • Abstract Number: 3133 • 2015 ACR/ARHP Annual Meeting

    The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is Mediated By the Urokinase Pathway Via Binding to Enolase-1 and Urokinase Plasminogen Activator Receptor

    Tetsuya Nishimoto1, Takahisa Takihara2, Logan Mlakar3, Yunyun Su4, Roger Chambers3 and Carol Feghali-Bostwick3, 1Department of Medicine, Medical University of South Carolina, Charleston, SC, 2Tokai University School of Medicine, Kanagawa, Japan, 3Medical University of South Carolina, Charleston, SC, 4Medicine, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Fibroproliferative disorders such as systemic sclerosis (SSc) have no effective therapies and result in significant morbidity and mortality. We recently demonstrated that the C-terminal…
  • Abstract Number: 3134 • 2015 ACR/ARHP Annual Meeting

    Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease

    Dinesh Khanna1, Carlo Albera2, Aryeh Fischer3, James R. Seibold4, Nader A. Khalidi5, Ganesh Raghu6, Lorinda Chung7, Elena Schiopu1, Dan Chen8 and Eduard Gorina9, 1University of Michigan, Ann Arbor, MI, 2University of Turin, Turin, Italy, 3National Jewish Health and University of Colorado, Denver, CO, 4Scleroderma Research Consultants LLC, Litchfield, CT, 5McMaster University, Hamilton, ON, Canada, 6University of Washington, Seattle, WA, 7Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 8Jazz Pharmaceuticals (formerly of InterMune), Palo Alto, CA, 9Formerly of InterMune, Brisbane, CA

    Background/Purpose: Interstitial lung disease (ILD) is a common and serious complication of systemic sclerosis (SSc). Pirfenidone, a novel antifibrotic agent, has been shown to be…
  • Abstract Number: 3135 • 2015 ACR/ARHP Annual Meeting

    Incidences and Predictors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal Study

    Veronika K. Jaeger1, Elina G. Wirz2,3, Yannick Allanore4, Gabriela Riemekasten5, Eric Hachulla6, Oliver Distler7, Paolo Airo8, Patricia E. Carreira9, Alexandra Balbir-Gurman10, Mohammed Tikly11, Serena Vettori12, Nemanja Damjanov13, Ulf Müller-Ladner14, Jorg HW. Distler15, Mangtao Li16, Ulrich A. Walker17 and EUSTAR collaborators, 1Department of Rheumatology, University Hospital Basel, Basel, Switzerland, 2Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, 3Department of Dermatology, University Hospital Basel, Basel, Switzerland, 4Department of Rheumatology A, Paris Descartes University, Cochin Hospital, Paris, France, 5Clinic of Rheumatology, University of Luebeck, Lübeck, Germany, 6Service de Médecine Interne, Hôpital Huriez, Université de Lille, Lille, France, 7Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 8UO Reumatologia ed Immunologia Clinica, Spedali Civili, Brescia, Italy, 9Servicio de Reumatologia, Hospital Universitario 12 de Octubre, Madrid, Spain, 10B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel, 11Division of Rheumatology, Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 12Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, 13Institute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia, 14Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, 15Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 16Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, 17Rheumatology, University Hospital, Basel, Basel, Switzerland

    Background/Purpose: Systemic sclerosis (SSc) is a rare and clinically heterogeneous autoimmune disorder characterised by fibrosis and microvascular obliteration of the skin and internal organs, particularly…
  • Abstract Number: 3136 • 2015 ACR/ARHP Annual Meeting

    Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review

    Annaliese Tisseverasinghe1, Ahmad Kadhim2, Ambica Parmar2, Louis Liu2 and Sindhu R. Johnson1, 1Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 2Division of Gastroenterology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: More than 90% of patients with Systemic Sclerosis (SSc) have gastroinstestinal (GI) involvement, commonly dysmotility causing complications such as gastroesophageal reflux and constipation. Treatment…
  • Abstract Number: 3137 • 2015 ACR/ARHP Annual Meeting

    Scleroderma Hand Contracture Study

    Joyce Joseph, Rheumatology, Univeristy of Teas Health Science Center at Houston, Houston, TX

    Background/Purpose: To investigate the progression of hand contractures in patients with systemic sclerosis and to identify disease features predictive of contractures. A sub-group analysis was…
  • Abstract Number: 3138 • 2015 ACR/ARHP Annual Meeting

    Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis

    Giacomo De Luca1, Silvia Laura Bosello1, Francesca Gabrielli2, Giorgia Berardi1, Federico parisi1, Manuela Rucco1, Giovanni Canestrari1, Leonarda Galiuto3, Filippo Crea3, Francesco Loperfido2 and Gianfranco Ferraccioli1, 1Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 2Division of Heart Failure and Cardiac Rehabilitation, Catholic University - Rome, Rome, Italy, 3Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose: Heart involvement is common during Systemic Sclerosis (SSc), even if often clinically silent, and represents the leading cause of death in about one third…
  • Abstract Number: 3139 • 2015 ACR/ARHP Annual Meeting

    Screening Algorithm for Pulmonary Hypertension in Systemic Sclerosis – Comparison of Predictive Accuracy of Three Algorithms

    Vivek Nagaraja1, Scott H. Visovatti2, Heather Gladue3, Veronica J. Berrocal4, Jennifer Serrano5, Vallerie McLaughlin2 and Dinesh Khanna6, 1Department of Medicine [Division of Rheumatology], University of Toledo, Toledo, OH, 2Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, 3Rheumatology, Emory University, Atlanta, GA, 4Div of Rheumatology, University of Michigan, Ann Arbor, MI, 5University of Michigan, Ann Arbor, MI, 6Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Pulmonary arterial hypertension (PAH) is the leading cause of mortality in systemic sclerosis (SSc), and is associated with a 3-year survival of approximately 50%.…
  • « Previous Page
  • 1
  • …
  • 1860
  • 1861
  • 1862
  • 1863
  • 1864
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology